Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX04-O vs Ranibizumab in wAMD
CTR20211925Phase 3Completed
- Sponsor
- Fosun Pharma
- Start
- Sep 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of HLX04-O in exudative macular degeneration, sponsored by Fosun Pharma. Started Sep 2021; status: completed.
02
Drugs
HLX04-O
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on CTR20211925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211925.